Search
for
Sort by
Research 331–360 of 787
- Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
- N6-methyladenosine (m6A)-circHECA from secondary hair follicle of cashmere goats: identification, regulatory network and expression regulated potentially by methylation of its host gene promoter
- Exploring novel management options for alopecia areata
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- Hidradenitis suppurativa: a new therapeutic approach for an old disease
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- 600 Impact of baricitinib on work productivity and indirect costs in adult patients with atopic dermatitis: A meta-analysis of clinical trials
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
- Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Extracellular vesicles from IFN-γ-primed mesenchymal stem cells repress atopic dermatitis in mice
- Research Progress in Chronic Autoimmune Urticaria
- Myeloproliferative disorder associated with alopecia universalis
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- mTOR signaling in hair follicle and hair diseases: recent progress
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders
- 151 High effectiveness of tildrakizumab over 52 weeks in patients with or without nail psoriasis: results from the phase IV POSITIVE Austrian subset